Global prevalence of psoriasis is ranging from 0.91 % to 8.5 % [1] . Exact numbers are missing for Slovakia. 1-5% range is the most probable while 2 % is also mentioned as an average prevalence for the European population. There is approximately 110 thousand patients suffering from psoriasis when extrapolating from total population of 5.5 million [2] . Extracutaneous manifestation is observed in 11-30 % of patients after years of solely skin symptoms presentation [3, 4, 5, 6] .
INTRODUCTION
Psoriatic arthritis (PsA) is a systemic inflammatory arthritis characterized by inflammation of peripheral joints, spinal inflammation, dactylitis and enthesitis that occurs in the context of psoriatic skin disease [7] . Up to 47 % of patients develop erosive changes within 2 years of disease onset [8] . Early diagnosis and institution of disease modifying anti-inflammatory pharmacological treatments have been shown to reduce irreversible joint changes and long-term morbidity [9, 10] . New medications, including biologics, have emerged with the potential to control inflammation and arrest the progression of joint damage [10] .
The incidence of PsA has been rising over the last 30 years in both males and females. Reasons for this increase may be related to a true change in incidence or greater physician awareness of the disease. The natural history of this disease is uncertain. Psoriasis severity has long been regarded as a poor clinical predictor of the development of PsA; however, a recent report has suggested the opposite [11, 12, 13] .
The PsA prevalence varies globally, based on the research performed during last decade. The exact prevalence of PsA in general and psoriatic populations is unknown. The prevalence in the U.S. general population was estimated 0.25 %, while prevalence of PsA among patients with psoriasis was 11 % [14] . Another report shows 2-3 % occurrence of inflammatory arthritis within general population, but 6-42 % range when considering psoriatic patients population only [15] . The exact epidemiological data regarding PsA prevalence in the general population of Central and Eastern European region are sporadic. It is estimated 0.05-0.24 % in Slovakia [16] , which is comparable to population-based study from Czech Republic with prevalence 0.05 % [17] . It is unclear whether this is due to a lower prevalence of the disease or an underestimation of symptoms, insufficient diagnosis or incorrect differential diagnosis of the inflammatory joint disease. Identifying the prevalence in the general population might prove difficult, therefore, the goal of this initial study is to measure PsA prevalence among psoriatic patients. Small epidemiology study, considering limited number of 933 biologically naïve severe psoriasis patients, was performed in 9 countries of the region. Prevalence of psoriatic arthritis in Slovakia was estimated 22 % when 175 patients were randomly screened. PsA was classified on the basis of the patient's self-report [18] .
Skin symptoms generally precede the first signs of arthritis [19] . PsA causes nonreversible joint damage and chronic pain if left untreated. Therefore the co-operation of two specialists in the area of autoimmune diseases, dermatovenereologist and rheumatologist is very important. Significant progress has been made in the Slovak Republic over the last decade in a disease symptoms recognition process by the general practitioners as well as dermatovenereology specialists. Biology therapy introduction was the main reason. The classification criteria for psoriatic arthritis were introduced into daily practice as Slovak rheumatologists became partners of international investigative teams [20] . The risk of an underdiagnosis comes from a small number of dermatovenereologists using proper assessment tools for the screening as well as low ability of the rheumatology experts to recognize predictive features determining PsA, e.g. presence of psoriasis, psoriatic nail dystrophy, dactylitis etc. Limited number of rheumatology outpatients in the country also causes diagnostic and treatment delays. The current first of a kind PsA epidemiology study in the region will utilize the specificity and sensitivity, of PASE and ToPAS questionnaires [21, 22] . The results obtained will be used to determine the prevalence of psoriatic arthritis among patients with psoriasis in the Slovak Republic. It is not possible to determine if an early diagnosis and treatment could result in significant health benefits, e.g. prevention of irreversible joint erosions. Neither it is possible to determine prognostic and risk factors for rapid structural progression. These should be an objective of the further research.
MATERIALS AND METHODS
This was prospective, non-interventional, epidemiological, observational study conducted using a survey administered to the psoriatic patients by their dermatologists. Patients diagnosed by the participating dermatologists were randomly recruited for the study with the aim of obtaining representative data. 43 regional dermatology outpatients (27 % of all dermatologists in Slovak Republic), distributed throughout the country were involved. Recruitment process lasted 9 months from October 2014 till July 2015.
The goal was to screen the first 10-20 consecutive eligible adult psoriasis patients visiting dermatology outpatient during screening phase -visit 1 of the study and agreeing to partici - Study population and inclusion criteria Enrollment in the study was based upon random selection of the first 10-20 consecutive adult (18+ years), de novo or chronic psoriasis patients, performed by the clinician in dermatology outpatient beginning screening phase. No histology confirmation, regardless of severity, disease duration, current or previous treatment, including patients with prior PsA diagnosis, willing to sign informed consent, residing in Slovak Republic and willing to travel to specialized medical centers. pate in the study. All recruited patients were screened for the presence of extra-cutaneous symptoms (i.e. joint pain, enthesitis, dactylitis, nail involvement) using questionnaires developed specifically to identify individuals that might be at high risk for the development of PsA (PASE and ToPAS questionnaires). Severity of the skin disease was determined by calculating PASI index [23] . Patients with previously confirmed PsA were terminated from the study at this phase. Patients without personal history of PsA and "positivity" of PASE and/or ToPAS (PASE ≥ 47, ToPAS ≥ 8) were referred to the university hospital-based dermatology center for the further evaluation. The patients fulfilling CASPAR criteria of newly diagnosed PsA were further evaluated at 1 of 4 specialized rheumatology clinics, during diagnosis phase -visit 3, where the diagnosis was either confirmed or denied [24] . According to the Slovak Ministry of Health guidelines, rheumatologists are the only specialists allowed to diagnose and treat PsA. Table 1 . Demographic data -patient age and sex, average height, weight and waist circumference 76.9 % of patients suffered from Psoriasis vulgaris, followed by P. capitis (7.2 %), P. unguium (4.2 %) and P. palmoplantaris (4.1 %). Other psoriasis forms were of minor prevalence only. The most frequent disease localization were upper (72.1 %) and lower (71.0 %) extremities and scalp (65.6 %). Nail lesions were observed in 29.0 % patients. Almost 2/3 (62.1 %) of patients had skin symptoms apparent on more than 10 % of the body surface while 39.6 % of patients PASI score was under 10. PASI value was not reported in 43.0 % of cases, therefore mean value for this variable was not determined (Table 2) . Mean age of patients at the disease onset was 29
Study objectives and outcome variables The primary study objective was -to determine the percentage of patients with a confirmed diagnosis of PsA among all psoriatic patients Secondary endpoints were: -to test the sensitivity and specificity of both ToPAS and PASE questionnaires -to determine possible risk factors of PsA
RESULTS
During the screening period (October 2014-July 2015), the total of 831 patients suffering from chronic psoriasis or newly diagnosed were enrolled in the study. 168 patients (20.8 %) of all enrolled patients were diagnosed for the first time. There was almost equal number of men (50.5 %) and women (47.9 %) even though 13 patients did not state their sex. While there were slightly more women (58.3 %) than men (40.5 %) in newly diagnosed group. Mean age at the time of visit was 40-59 years in both groups and sexes, while 44.5 % (newly diag. 54.4 %) were men of that age and 45.7 % (56.1 %) were women. There was apparent small overweight in both groups. Average BMI for men was 28.1 and for women 27.2. Complete distribution of basic demographic values is available in Table 1 . Table 3 . Positive or negative diagnosis frequency of PsO, PsA/Reactive arthritis within family history and rheumatology specialist confirmed PsA within personal anamnesis (pts -patients, all pts -whole study population, new diag pts -newly diagnosed PsO patients, RHEUM -rheumatology specialist)
Positive family history regarding psoriasis was reported by 41.3 % (40.5 %) of patients among which 59.8 % (58.8 %) were the first degree and 35.6 % (42.6 %) were the second degree relatives. Family history of psoriatic and/or reactive arthritis was positive in 10.0 % (17.9 %) cases. However 26.2 % (27.3 %) patients either did not know or did not report the possible link to rheumatic disease in their relatives. Rheumatology specialists diagnosed PsA in 21.8 % of all patients enrolled into the study (either prior or de novo) 32 patients (3.8 %) among newly diagnosed PsO patient group were suspect of PsA according to PASI (mean value 5.4), PASE (47.5) and TOPAS (8.5) assessment outcome. They were referred to 4 rheumatology clinics. 9 new patients (1.08 %) were confirmed PsA diagnosis, by applying CASPAR criteria (mean value 4.2), FW (13.5 mm/h), CRP (5.8 mg/l) criteria, which is 28.1 % of all suspected patients (Tab. 3).
The average age at PsA disease onset was 33.8 years. 38.1 % of patients were diagnosed with PsA at the age of >40 years (Table 4) . Rheumatology specialists are visited by 95.8 % of PsA patients to get the treatment. 68.4 % of patients are controlled regularly while 27.3 % visit rheumatologist less than once a year.
PsO treatment options were divided into three general categories: local therapy (77.3 % patients), phototherapy (10.8 %), systemic therapy (26.4 %). Systemic therapy duration was recorded in years. Mean retinoid treatment duration was 2 years, cyclosporine 2 years, methotrexate 3 years and biologics 6 years. Average score for PASE questionnaire assessment was 37 and for ToPAS, it was 6. years. The onset age range was almost equally distributed starting from second decade (23.7 %) to the fifth decade (23.6 %). Disease initiation is minimal before and after this interval (Table 4) . Table 4 . Patient age at PsO and PsA disease onset (years) Fig. 2 . Co-morbidities prealence in total study population and newly diagnosed patients (%) A comparison of the potential risk factor between psoriasis and PsA has been as follows: weight 81 vs. 82 kg, BSA 20 vs. 24, and PASI 9 vs 10, respectively. 100 % of total 831 patients screened returned the questionnaires ToPAS and PASE. The sensitivity (72.6 % vs 58.9) and specificity (81.3 vs 80.5) of ToPAS was higher compared to PASE, while sensitivity was significantly better (P=0.01). Fisher-Irwin test was used to evaluate statistical significance (Fig. 3) .
DISCUSSION
This research was set up to help to improve health care in Slovakia and all of Eastern Europe by raising awareness about psoriatic arthritis disease among patients, primary care physicians 43.4 % (54.8 %) of patients suffered from previous or current co-morbidity usually related to metabolic syndrome. The most frequent co-morbidity was hypertension 22.3 % (23.2 %), followed by diabetes mellitus 4.1% (2.4 %) and hepatopathy 3.6 % (1.8 %) Other concomitant diagnosis were of minor prevalence (Fig. 2) . and dermatologists. This can be achieved through publicizing accurate data about disease prevalence, new diagnostic tools, such as validated questionnaires and state-of-the-art radiological techniques. In addition, the obtained data should serve as a source of information for conducting broader clinical trials focused on the pathogenesis of the disease, its prognostic and predictive factors, and new treatment modalities.
The lack of quality epidemiology data, not only within the CEE region but globally and limited options to provide primary contact physicians with proper diagnostic tools emphasize urgent need for similar studies in many different areas. The main goal should be always the earliest possible patient diagnosis to prevent irreversible changes by setting up proper treatment course. Early intervention will avoid the second or third choice therapy options usage, which needs to be often carefully considered due to possible side effects and higher costs. Rising costs and appropriate budget allocation are of great importance to secure sufficient resources for particular diagnosis.
It was not the study objective to determine psoriasis incidence and prevalence. However the research sample of 831 eligible psoriasis patients confirmed that there is low disease prevalence in the population <10 year old. The first onset was usually between 10-19 years. The peak prevalence (44.9%) was apparent between 40-59 years of age in chronic psoriasis population and even more evident (56%) in the newly diagnosed patient group of the same age range. If compared to the age of the first disease onset, there is no peak in any age group when children under 10 are not included. Type I psoriasis (<40 years) was present in 44.3% and type II psoriasis (>40 years) was recorded in 44.2 %. These results not exactly correlate with a current evidence where 70 % of all psoriasis should be type I psoriasis [25, 26] . It is very interesting to observe that despite random selection there was fivefold increase of type II (82.7 %) compare to type I (16.1 %) in newly diagnosed patients. There might be slight correlation between increased frequency of co-morbidities and higher psoriasis prevalence in older patients [27, 28] . The proportion of women suffering from psoriasis among newly diagnosed patients was lower than men in the age group of 20-39 years (13.3 % vs 20.6), but it was steadily growing and surpassing the men in the age group of 60-80 years (29.6 % vs 23.5 %). Female hormones can significantly affect the biological and immune changes in the skin. Thus severity of psoriasis in women can fluctuate with hormonal changes throughout patient life [29] .
Family history was reported due to the significant impact of genetic background on the disease prevalence. 41.3 % of patients reported psoriasis symptoms family occurrence, while the first line relatives were 59.8 %. Since the global data available show wide variation in family history ranging from 6.4% to 91 %, our results should be considered in line with expectations,
even though previously observed frequency in CEE region population was 55 % (36 %), that is similar to the one observed in Scotland 61.1 % (40 %) [30, 6, 31] . Psoriasis vulgaris was confirmed to be the most prevalent form of psoriasis, being in line with current evidence [32] . The study confirmed that the most frequently affected body parts are upper and lower extremities and scalp followed by trunk, even though the bigger patient sample lowered previously observed values for every entity [6] . The estimation of disease severity, based on psoriatic body surface area affected (BSA), revealed that 62.1% of patients suffered from moderate to severe psoriasis >10 % BSA [33] . Psoriasis severity could not be assessed based on European consensus since more than 43 % patients did not have their PASI scores reported and no life quality index was used [34] . The results indicate similarity with those obtained for CEE region in Palotai et al. epidemiology study, but are contrary to data from other western countries despite sometimes different methodology used to evaluate moderate to severe psoriasis ≥ 3 % BSA [35, 36] .
The subjective overestimation of BSA affected by dermatovenereologists diagnostic habit, could be the reason for the high severe patient share. Only about one quarter of all patients would be considered moderate to severe, based on the assumption of severe disease course and systemic therapy usage correlation. This would be in line with global data. It can be concluded that there is a clear trend toward lower usage of any treatment modality except biologics. Government restrictions on phototherapy providers, changing status of most topical therapies from fully covered by health insurance budget to co-paid or fully out of pocket, as well as the public campaign about possible side effects from long-term usage of systemics, lowered the penetration across whole therapy portfolio during last seven years [18] .
The current evidence supports the idea of association between psoriasis and obesity. Even though especially severe psoriasis and psoriatic arthritis is considered independent risk factor for cardiovascular diseases [37] . Our research revealed that only 2 % of psoriatic patients had diagnostically confirmed obesity compared to 29.7 % prevalence in general Slovak population [38] . This would support the above mentioned argument that psoriasis is independent risk factor and precedes obesity or the hypothesis that BMI is less effective biomarker compare to waist to height ratio when considering patient obesity. Applying of this measure would lead to identification of obesity in majority of the patients [39, 40] . There was an evident trend toward metabolic syndrome (MS) when five out of six most prevalent co-morbidities, despite low prevalence, were of metabolic origin [41] . Arterial hypertension is the most prevalent comorbidity in contrast to low frequency of obesity, diabetes and impaired lipid profile. It is not corresponding to the current knowledge about particular MS components. Even the association between previous long-term use of cyclosporine A (sometimes over 5 years in Slovakia) and rise of MS could not explain this paradox [42, 43] . The possible explanation is that majority of the patients were not yet followed up in cardiology, endocrinology or internal medicine specialists, because the aforementioned usually chronic diagnosis have onset at higher age comparable to general population especially when the patient is properly treated for skin symptoms in dermatology gene ral practice [44, 45] .
The proportion of prior to study diagnosed PsA cases was higher than previously published [6] . The number of newly diagnosed, rheumatologist confirmed PsA patients was only marginal, contrary to some other countries [46, 3] where the results might be impacted by the bias of small patient sample and not standardized selection criteria. The number of undiagnosed PsA patients is comparable, if similar criteria are applied while using PASE questionnaire, followed by CASPAR criteria evaluation [47] . Overall estimated prevalence of PsA among patients with psoriasis is consistent with expectations [3, 4, 5, 6] . The mean age relative to disease prevalence is similar to some small population based studies despite the small patient study group [48] . The observed age of disease onset partially reflects current knowledge on PsA epidemiology [9] . The majority of patients have their symptoms first occurrence after 30 years of age however the occurrence between 20-29 and 30-40 is comparable. The typical correlation between PsO onset and approximately one decade postponement of the joint symptoms occurrence is visible when comparing data in Table 4 [49] .
ToPAS test was more efficient in this study compared to PASE. Especialy its sensitivity was significantly better. The values are within expected wide range based on the current scientific knowledge. The limitations coming from lower nonpolyarticular cases detection potential were compensated by application of ToPAS v.2. It was chosen as a more appropriate screening instrument, since it includes important axial domain which scored high in this study among other symptoms. While PASE was used in its original version. This is the possible explanation of the differences in test sensitivity value [50, 51, 52] .
CONCLUSION
This is a first screening of PsA in Slovakia. Our epidemiology study could not answer all possible questions that arose during the data analysis. The further research is needed in the area of the standardization, regarding disease severity evaluation among dermatovenereologists would be needed. The research on association between the comorbidities and PsA prevalence ratio. The correlation between low number of newly diagnosed PsA patients and dermatology outpatient diagnostic standards applied in Slovakia must be verified. Two main goals for the future would be to organize a network of dermatologists and to develop a mechanism for collecting and analyzing clinical data in short term. Establish an interdisciplinary research network involving dermatologists, rheumatologists and primary care physicians. Use the network for future collaborative research projects focusing on psoriasis and broader clinical research of autoimmune diseases, followed by the long-term goals: 1) to determine the prevalence and identify risk factors of the early progression in a large, relatively homogenous population in Slovakia.
2) to acquire data and expertise to create diagnostic and treatment guidelines for psoriatic arthritis and its complications.
3) to better understand the natural history of the disease.
